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Abstract
Ewing sarcoma and osteosarcoma represent the two most common primary bone tumours in childhood and adolescence,
with bone metastases being the most adverse prognostic factor. In prostate cancer, osseous metastasis poses a major
clinical challenge. We developed a preclinical orthotopic model of Ewing sarcoma, reflecting the biology of the tumour-
bone interactions in human disease and allowing in vivo monitoring of disease progression, and compared this with models
of osteosarcoma and prostate carcinoma. Human tumour cell lines were transplanted into non-obese diabetic/severe
combined immunodeficient (NSG) and Rag22/2/cc2/2 mice by intrafemoral injection. For Ewing sarcoma, minimal cell
numbers (1000–5000) injected in small volumes were able to induce orthotopic tumour growth. Tumour progression was
studied using positron emission tomography, computed tomography, magnetic resonance imaging and bioluminescent
imaging. Tumours and their interactions with bones were examined by histology. Each tumour induced bone destruction
and outgrowth of extramedullary tumour masses, together with characteristic changes in bone that were well visualised by
computed tomography, which correlated with post-mortem histology. Ewing sarcoma and, to a lesser extent, osteosarcoma
cells induced prominent reactive new bone formation. Osteosarcoma cells produced osteoid and mineralised ‘‘malignant’’
bone within the tumour mass itself. Injection of prostate carcinoma cells led to osteoclast-driven osteolytic lesions.
Bioluminescent imaging of Ewing sarcoma xenografts allowed easy and rapid monitoring of tumour growth and detection
of tumour dissemination to lungs, liver and bone. Magnetic resonance imaging proved useful for monitoring soft tissue
tumour growth and volume. Positron emission tomography proved to be of limited use in this model. Overall, we have
developed an orthotopic in vivo model for Ewing sarcoma and other primary and secondary human bone malignancies,
which resemble the human disease. We have shown the utility of small animal bioimaging for tracking disease progression,
making this model a useful assay for preclinical drug testing.
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Introduction
The complex three dimensional anatomy of bone undergoes
constant remodelling dependent upon the coordinated activities of
multiple resident cell types. The growth of primary or metastatic
cancer cells within the bone disturbs this equilibrium, producing
clinically important changes in bone structure including aberrant
new bone formation and bone destruction [1]. These changes may
have significant clinical consequences such as severe bone pain,
nerve compression syndromes, hypercalcaemia, cytopenias and
pathological fractures, which may not only reduce quality of life
but in many cases correlate with reduced survival [2,3,4].
Moreover, interactions with resident bone cells are critical for
the intraosseous growth of the tumour.
Specific, and distinct, interactions with bone are central to the
pathogenesis of Ewing sarcoma and osteosarcoma, the two most
common primary bone sarcomas of children and young people.
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The majority of Ewing sarcomas arise in bone, with the femur,
pelvis and humerus most often affected. Osteosarcomas are often
localized to the metaphyseal region of long bones, with the region
around the knee involved in around 60% of cases [5]. For both
tumours, metastatic osseous spread is a feature of poor prognosis
disease. While two thirds of Ewing sarcoma patients with localized
disease can be cured, the 5-year event free survival in patients
presenting with osseous metastases/bone marrow infiltration is
only 10–20% [6–8]. Furthermore, bone tissue is one of the most
common sites of metastatic disease in common cancers such as
carcinoma of the prostate. More than two thirds of patients with
advanced prostate carcinoma develop bone metastases conferring
a poor prognosis, with the axial skeleton most frequently affected
[9].
The pathophysiology of bone remodelling and intraosseous
tumour growth in bone cancers such as Ewing sarcoma is still
unclear and requires further investigation. Similarly, while the
basic mechanisms by which tumours such as prostate carcinoma
home to the bone marrow cavity and interact with the cells in the
metastatic niches of bone have been explored, a detailed
understanding is still lacking [10–14]. This lack of understanding
has prevented the development of effective treatments for osseous
disease. The validation of clinically relevant preclinical models will
provide tools with which to both study the mechanisms involved in
disease progression, and examine novel treatments directly
targeting the interaction of tumour cells with the bone microen-
vironment.
Currently, many preclinical models of bone cancer, particularly
those of Ewing sarcoma, use subcutaneous or intramuscular
xenografts, which clearly do not mirror the site of disease in
patients [15]. Metastatic intravenous models of Ewing sarcoma in
non-obese diabetic/severe combined immunodeficient (NSG)
mice show a pattern of disease spread similar to that found in
patients, providing a suitable system for studying metastasis of this
disease. However, only 23% of the experimental mice in these
studies developed assessable bone metastases [16]. To facilitate
better preclinical study of primary bone tumours and their
metastatic spread, and of bone metastases of cancers such as
prostate carcinoma, it is desirable to develop orthotopic models
that involve direct injection of cancer cells at the clinically relevant
site. Intrafemoral injection in immunocompromised mice provides
a technically feasible and reproducible approach to such models
[17] giving rise to tumours that are detectable by palpation or
in vivo imaging of the animals and closely resemble those found
clinically. Intrafemoral injection is a minimally invasive and non-
traumatic procedure, as are some intratibial transplantation
techniques [18;19;20].
The major difficulty in using preclinical orthotopic models of
any cancer has been the measurement of disease burden in a non-
accessible site. The use of in vivo imaging offers the opportunity to
detect and monitor development and progression of the disease.
Small animal imaging technologies such as positron emission
tomography (PET), computed tomography (CT), magnetic reso-
nance imaging (MRI) and bioluminescent imaging are thus
becoming powerful tools to monitor tumours in orthotopic disease
models. In this study we have therefore used intrafemoral
injection, combined with in vivo imaging approaches, to develop
a preclinical orthotopic model for Ewing sarcoma. We have
compared the bone changes induced by Ewing sarcoma to those
induced by osteosarcoma and prostate carcinoma to validate the
model as one in which specific interactions of both primary and
secondary bone tumours with the bone itself can meaningfully be
investigated.
Materials and Methods
Definition of Experimental Outcomes
Primary outcomes assessed in this study were: tumour formation
and growth, destructive bone changes mirroring the human
disease (histology, CT findings) and imaging of primary tumour.
The secondary outcome assessed was the detection of distant
tumour spread by imaging techniques.
Cell Lines and Cell Culture
Two established human Ewing sarcoma cell lines were used for
transplantation of mice. TC-71 originated from a local Ewing
sarcoma relapse in the humerus [21]. VH-64 cells were established
from a malignant pleural effusion in a patient with Ewing sarcoma
of the metatarsal bone [22]. SaOS-2 is an established osteosar-
coma cell line derived from a primary osteosarcoma [23]. PC3M is
an established prostate carcinoma cell line derived from a mouse
liver metastasis arising from xenotransplantation of an osteolytic
bone metastasis of a prostatic adenocarcinoma [24,25].
All cell lines were cultured in Roswell Park Memorial Institute
(RPMI) 1640 medium (Sigma, Germany) containing 10% FCS
(foetal calf serum) and 2 mM glutamine at 37uC in a humidified
atmosphere with 5% CO2. Ewing sarcoma cells were grown in
collagen-coated tissue culture flasks.
Transduction of TC-71 Cells
A protocol described previously [26] to transduce lymphoblastic
leukaemic blasts was adapted to transduce Ewing-sarcoma cells
with a lentiviral vector (pSLIEW) encoding both enhanced green
fluorescent protein (EGFP) and firefly Luciferase (fLuc), allowing
in vitro analysis and cell sorting (EGFP) and in vivo bioluminescent
imaging (fLuc). The SLIEW virus was produced by transfection of
HEK293T cells with equimolar amounts of a packaging vector
(pCMVD8.91), an envelope vector pMD2.G and the pSLIEW
transfer vector. For transductions, TC-71 cells were grown for 24
hours on collagen coated 48-well plates before 100 ml viral
suspension and 8 mg/ml polybrene were added and viral
transduction was performed by spinfection at 1500 g for 2 h at
32uC. Plates were further incubated at 37uC/5%CO2 and
medium was replaced by fresh medium the day after. Transduc-
tion efficiency (percentage of EGFP positive cells) was assessed 3–4
days after transduction and prior to i.f. injection by flow cytometry
(FACSCalibur, Becton Dickinson, Oxford, UK) using Cell Quest
Pro Software, version 5.2.1. Either 25% EGFP positive or sorted
100% positive EGFP cells were used in 3 experiments.
Ethics Statement
All animal studies were performed by personnel who had
completed approved Home Office training and held current
Personal Licences under the Animals (Scientific Procedures) Act
1986. All in vivo experiments were performed in line with current
Home Office regulations and compliant with the 3R principles
(Home Office license number PPL 60/3846) and therefore no
further ethics approval was required. Animals were kept under
specific pathogen free conditions, and all experimental manipu-
lations with mice were performed under sterile conditions in a
laminar flow hood except imaging. Intrafemoral injections and all
imaging procedures were performed on anaesthetized mice and all
efforts were made to minimise suffering.
Mice and Intrafemoral Transplantation
NSG mice were transplanted with 16106 cells at a median age
of 12 weeks (range 10–3 weeks), Rag22/2 cc2/2 mice with
16103–16106 cells at 12 to 17 weeks. For intrafemoral
Mouse Models and In Vivo Imaging for Bone Cancers
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Table 1. Experimental mice for the development of an orthotopic model of bone malignancies.
Transplanted cell line
Number
of mice
Age at transplantation,
weeks: median, (range)
Time to reach protocol
limits, days: median,
(range)
Tumour formation,
%
Dominant histological
feature
VH-64 7 12 (11–12) 38 (31–55) 100% (7/7) Extensive spicules of
reactive new bone
TC-71 6 12 (11–12) 31 (15–42) 100% (6/6) Reactive new bone and
cortical destruction
TC-71 in Rag22/2
cc2/2 mice
13 13 (12–17) 43.5 (4–62) 92% (12/13) As for TC-71
SaOS-2 5 12 (10–12) 70 (52–85) 100% (5/5) Malignant new bone
formation
PC3M 7 12 (12–13) 29 (29–55) 100% (7/7) Osteoclastic cortical lysis
and reactive new bone
Medium 5 11 (11–12) N.A. (sacrificed.day 85) 0% (0/5) Normal findings
VH-64 and TC-71: Ewing sarcoma cell lines; SaOS-2: osteosarcoma cell line; PC3M: prostatic adenocarcinoma cell line; Medium: mice were injected with medium alone.
N.A.: not applicable. All mice were NSG mice unless stated otherwise.
doi:10.1371/journal.pone.0085128.t001
Figure 1. Prominent reactive bone formation following transplantation of Ewing sarcoma cell lines VH-64 (A–E) and TC-71 (F–I). A,
Representative CT image of a VH-64 transplanted femur 42 days after transplantation showing a ‘‘sunburst’’ pattern of reactive bone formation. B,
Representative Maximum Intensity Projection CT image of a mouse with a VH-64 tumour 52 days after transplantation showing a ‘‘sunburst’’ pattern
of reactive bone formation on the transplanted femur (between arrows, and extending proximally along the femur). C, Extensive reactive bone
(arrows) arcing through a VH-64 tumour accompanied by foci of cartilage (arrowheads). Tumour is partly necrotic (N) (H&E, original magnification
206). D, Reactive bone emanating from femoral cortex (top) within a VH-64 tumour (H&E, original magnification 1006). E, Reactive new bone
formation partially lined by osteoblasts (arrows) amongst VH-64 tumour cells. A single multinucleate osteoclast (arrowhead) is also present (H&E,
original magnification 4006). F, Reactive bone and a focus of cartilage (arrow) amongst VH-64 tumour cells (H&E, original magnification 2006) G,
Representative CT image of a TC-71 transplanted femur 15 days after transplantation showing cortical destruction (arrow) and possible reactive new
bone formation (arrowhead). H, Marked reactive new bone formation within a TC-71 tumour, beneath the raised periosteum (arrow). Cortical
destruction is seen distally (arrowhead) (H&E, original magnification 406). I, Reactive new bone in a TC-71 transplanted mouse, lined by osteoblasts
(arrow) clearly distinct from infiltrating tumour cells (arrowhead) (H&E, original magnification 4006).
doi:10.1371/journal.pone.0085128.g001
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Figure 2. ‘‘Malignant’’ bone formation within the tumour mass after SaOS-2 transplantation. A, Representative CT image 70 days after
intrafemoral transplantation of SaOS-2 cells showing ‘‘malignant’’ bone formation within the extraosseous tumour mass (arrow). B, Representative
Maximum Intensity Projection CT image of a mouse bearing a SaOS tumour 70 days after transplantation, showing ‘‘malignant’’ bone formation
within the extraosseous tumour mass (arrow). C, ‘‘Malignant’’ bone forming amongst tumour cells in the medullary cavity, showing appositional
deposition (scaffolding) on existing bone trabeculae (‘‘T’’) (H&E, original magnification 2006). D, Left panel: malignant tumour cells amongst pale
eosinophilic osteoid which is partially mineralised (arrow) (H&E, original magnification 4006). Right panel: fine, randomly arborising strands of
mineralised osteoid (‘‘malignant’’ bone) amongst SaOS-2 tumour cells (H&E, original magnification 4006).
doi:10.1371/journal.pone.0085128.g002
Figure 3. Osteolytic lesions caused by injection of PC3M. A, Representative CT image 29 days after transplantation of PC3M cells, showing
lytic destruction of the femur (arrow) (sagittal section). B, Lytic destruction of the femoral cortex associated with numerous osteoclasts (short arrow)
and focal reactive bone formation (long arrow) (H&E, original magnification 2006). C, Lysis and virtual destruction of the bone by numerous
osteoclasts on the periosteal surface (long arrows), with osteoblastic reaction on the medullary surface (short arrow) (H&E, original magnification
2006). D, Lysis of bone by osteoclasts in resorption pits on the medullary surface (arrows), clearly distinct from intrafemoral tumour (H&E, original
magnification 4006).
doi:10.1371/journal.pone.0085128.g003
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transplantation, cells were injected directly into the right femur of
male NSG mice (JaxH mice strain name: NOD.Cg-Prkdcscid
Il2rgtm1wjl/SzJ) or Rag22/2 cc2/2.mice (JaxH mice strain name:
C;129S4-Rag2tm1.1Flv Il2rgtm1.1Flv/J). Both mouse strains lack NK
cell, B and T lymphocyte activity [27;28], minimising the chance
of xenograft rejection. Rag22/2 cc2/2 mice were chosen in
addition to NSG mice as the latter harbour a DNA-PK defect
which could confound future experiments using DNA repair
inhibitors. The procedure for intrafemoral injection was previously
described [17;29].
Briefly, mice were anaesthetized with an Isofluorane-oxygen gas
mixture (approx. 2.5% Isofluorane and 0.5l O2 per minute).
Carprofen (RimadylH, Pfizer, Surrey, UK), 50 mg per 10 g body
weight, was injected subcutaneously as an analgesic. The right
knee was flexed, the femur was punctured with a 25 Gauge needle
and cells were injected with a 30 Gauge insulin syringe through
the knee joint into the right femur. Control transplantations were
performed by injection of the right femur with medium only. For
experiments using NSG mice, 16106 cells were injected in a 30 ml
volume. For experiments using Rag22/2 cc2/2 mice, either
16104–16106 cells in 30 ml medium (experiments 1 and 2) or
16103–16104 cells in 10 ml medium (experiment 3) were injected.
Histology
Organs and tumour masses were fixed in 10% neutral buffered
formalin (4% formaldehyde in phosphate buffered saline). Fixed
hind limbs bones were decalcified in situ in 10% formic acid or in
14% neutral EDTA solution until suitable for microtomy.
Subsequently, tissues were embedded in paraffin, and 4–5 mm
thick sections were prepared and stained with hematoxylin and
eosin.
CT Imaging
After i.f. injection and before reaching protocol limits, each
mouse was subjected to two or up to a maximum of five CT scans
using the Bioscan NanoCT scanner (Bioscan, Paris, France). These
were performed before each PET scan using a transferable animal
bed so that animals were kept in the same position to allow
accurate subsequent fusion of PET and CT image datasets.
The field of view for the scans was 150 mm675 mm.
Parameters for whole body images were: standard resolution,
180 projections, 55 kVp, 1000 ms exposure time and 10–12 min
acquisition time, leading to a dose of ,150 mGy. The parameters
for scans of a higher resolution taken from just the lower limbs
were: ultra-fine resolution, 360 projections, 45 kVp, 400 ms
exposure time, 2–3.5 min acquisition time, leading to a radiation
dose of ,105 mGy. The images were reconstructed using Exact
Cone Beam FBP (Filtered Back Projection) with the SheppLogan
filter. The resulting voxel/pixel size is 0.10/0.096 mm.
PET Imaging
PET imaging was performed on 5 mice injected with Ewing
sarcoma cells, on 5 mice injected with osteosarcoma cells, on 2
animals injected with prostate cancer cells and on 2 control
animals. For 5 mice, the first PET scan was performed
approximately three weeks after intrafemoral injection of tumour
cells with follow-up PET scans 3–4 weeks after the initial PET,
depending on the development of disease. All other animals had
PET scans performed around 7 weeks after i.f. injection. 2-
[18F]fluoro-2-deoxy-D-glucose (FDG) was purchased from IBA
Molecular UK Ltd. (Sheffield, UK). The tracer was diluted with
sterile saline if required. PET scans were performed with a high-
resolution Philips Mosaic HP preclinical PET system (Philips
Medical Systems, Eindhoven, The Netherlands) with a field of
view of 1286120 mm. Before tracer injection, mice were
anaesthetised either with inhalation of Isoflurane-oxygen gas
mixture (approx. 2% Isoflurane, 0.5 l/min oxygen) or intraper-
intoneal injection of ketamine (50–75 mg/kg) plus medetomidine
(0.5–1.0 mg/kg) in a volume of 10 ml/kg. Mice anaesthetized with
Isofluran/oxygen were kept under anaesthesia for the entire
experimental procedure using a Minerve Animal Anaesthesia
System (Equipement Ve´te´rinaire Minerve, Esternay, France).
Rectal temperature was maintained at physiological values by
use of a heating pad between the start of the anaesthesia and the
experimental procedures. Scans were performed 1 hour after an
intravenous injection of 10 MBq FDG. Within the machine, the
body temperature was maintained by heated air flow through the
animal bed. All mice were observed until fully recovered from
anaesthesia.
Reconstruction of PET images was performed using the 3D-
RAMLA algorithm with no attenuation correction. Quantitative
PET imaging results are reported in terms of standardised uptake
value (SUV) with both SUVmean (mean of pixel SUV values
within a defined region of interest) and SUVmax (maximum pixel
value in that region of interest) presented.
MR Imaging
One week after the last CT scan (8–9 weeks), 2 mice
transplanted with Ewing sarcoma (VH-64) and 2 injected with
prostate carcinoma (PC3M) cells underwent a final MRI scan.
Two mice transplanted with osteosarcoma cells (SaOS-2) and 1
control mouse were scanned after 12 weeks. MRI scans were
performed with a high-resolution 7Tesla Varian MR system
(Varian Inc., Palo Alto, USA) using a Rapid 72 mm quadrature
1 H volume coil (RAPID Biomedical GmbH, Rimpar, Germany).
Mice were anaesthetised for the entire experimental procedure by
Isoflurane/oxygen inhalation (approx. 2% Isoflurane, 0.5 l/min
oxygen).
Parameters for the lung scans were: fast spin echo sequence with
respiratory gating, repetition time (TR) 2000–2500 ms, effective
echo time (TE) 37–48 ms, matrix 2566256 with echo train length
Figure 4. PET-CT imaging of primary tumour. A, PET/CT image of
a mouse with a VH-64 tumour following intrafemoral transplantation.
Image taken 52 days after transplantation, tumour marked with a white
arrow (Maximum Intensity Projection CT image overlaid with FDG-PET
image, dorsal view, ketamine/medetomodine anaeshesia). B, PET/CT
image of a mouse injected with medium alone, also 52 days after i.f.
injection, no tumour visible (Maximum Intensity Projection CT image
overlaid with FDG-PET image, dorsal view, ketamine/medetomodine
anaeshesia).
doi:10.1371/journal.pone.0085128.g004
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8, field of view 40640 mm, in plane resolution 0.16 mm and slice
thickness 2 mm. Parameters for the leg scans were: spin echo
sequence, TR 500 ms, TE 17 ms, field of view 30635 mm, in plane
resolution 0.13 mm and slice thickness 2 mm, giving a T1
weighted sequence.
For calculation of tumour volumes the software Vnmr J
(Varian/Agilent) Version 3.1A was used. 1 H MR images (fast-
spin echo with TR=2000 ms, effective TE 39–48 ms, echo train
length 8) were obtained from 1 mm or 2 mm thick slices with a
field of view 40 mm640 mm and matrix size 2566256, corre-
sponding to an in-plane spatial resolution of 0.16 mm. For each
slice in which tumour was identified, a region of interest was
drawn around the tumour and the area of that region determined
using the region of interest tool in VnmrJ. The areas of all tumour-
containing slices were summed to estimate the tumour volume.
Bioluminescent Imaging
Rag22/2 cc2/2 mice transplanted with luciferase-expressing
TC-71 cells underwent weekly non-invasive whole-body imaging
starting 1 week after intrafemoral injection using the IVIS
Spectrum Imaging system (Caliper Life Sciences, Hopkington,
MA, USA). Mice were injected i.p. with 3 mg/100 ml of luciferin
solution before being anaesthetized for the procedure. To avoid
unintentional injection of the substrate into the gut, mice in
experiment 3 were injected subcutaneously (s.c.) with 150 mg
luciferin/g body weight. Ten or twelve minutes after i.p. or s.c.
Figure 5. Comparison of different anaesthetic techniques. Representative FDG-PET images of mice anaesthetized with isofluorane (right
mouse) versus ketamine/medetomidine (left mouse) showing a marked reduction in cardiac FDG uptake in the latter.
doi:10.1371/journal.pone.0085128.g005
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injection, images were acquired for 0.5 to 300 seconds. The
photon emission from the animals was captured and quantitated in
p/s/cm2/sr using Living Image software (Version 4.3.1., Caliper
LifeSciences).
Results
Success of Transplantation Strategy and Time Course of
Induced Tumours
Each cell line injected gave rise to tumour within the medullary
cavity of the femur, bone destruction, and growth of extra-
medullary tumour masses showing variable degrees of necrosis.
The tumour growth of transplanted prostate carcinoma cell line
PC3M required euthanasia of experimental mice 29 days (median)
after transplantation, the shortest time to reach protocol limits,
whereas animals transplanted with SaOS-2 osteosarcoma cells
lived 70 days (median) after transplantation (Table 1). NSG mice
transplanted with Ewing sarcoma cell lines survived 31–38 days
(median), Rag22/2 cc2/2 mice survived for 43.5 days (median).
With the exception of one Rag22/2 cc2/2 mouse and the control
mice transplanted with medium alone, all experimental animals
developed tumours at the site of injection (Table. 1). Taken
together, both mouse strains proved to be excellent recipients for
bone cancer orthotopic xenografts with a ‘‘take rate’’ of almost
100%.
Histology and Corresponding CT Findings
Each different type of cell line transplanted had characteristic
predominant effects on the bone, reflecting the range of changes
seen in patients with these tumours. Supporting Fig. S1 illustrates
the CT and histological appearances of control mice injected with
medium alone for comparison. The histological and CT imaging
appearances of these control mice were normal.
VH-64 Ewing sarcoma cell line. CT images of the femurs
injected with VH-64 cells were notable for the presence of new
calcified material extending outward from the surface of the
injected femur (Fig. 1A, B). In most cases these manifested as
prominent spicules radiating perpendicularly from the surface in a
‘‘sunburst’’ or ‘‘sunray spicule’’ pattern. This pattern tended to
overshadow destructive changes on CT scans. Histological
examination (Fig. 1C–F) showed numerous and extensive spicules
of reactive bone amongst tumour cells, but often associated with
osteoblasts, extending in a perpendicular manner away from, and
continuous with the periosteal surface of the femur. In many areas,
these were associated with cortical destruction and appeared
beneath a raised periosteum, but such bone was sometimes present
amongst tumour cells significantly away from the femur. This
reaction was also associated with the formation of islands of
reactive cellular cartilage, often within bands of loose fibrous
tissue, amongst the tumour mass. In some mice similar, but less
marked, changes were also seen on the non-transplanted fibula.
Figure 6. MR imaging of primary tumour with measurement of tumour volume. Measurement of a VH-64 Ewing sarcoma of the injected
femur with a large extra-osseous tumour component. The regions of interest (within red markings) were measured in sequential 2 mm thick slices
that showed tumour, and by adding the volumes of individual slices the total tumour volume was calculated. In the depicted case the estimated total
volume was 492 mm3 (tumour in 6 slices; region of interest per slice: 22 mm2, 42 mm2, 57 mm2, 59 mm2, 52 mm2, 14 mm2; total area = 246 mm2;
slice thickness = 2 mm; estimated total volume= 492 mm3).
doi:10.1371/journal.pone.0085128.g006
Figure 7. MR images of liver deposits and lungs using
respiratory gating. MRI imaging performed 47 days after injection
of a mouse with VH-64 cells, providing an example of respiratory gating
to obtain good quality images. 2 out of 25 adjacent 2 mm slices
(selected slices 12 mm apart) are presented showing upper abdomen
(left panel), revealing a large liver tumour, and lungs (right panel).
Despite slight movement artifacts on the thoracic images there is good
visualisation of the lung fields. L: liver; K: kidney; S: stomach.
doi:10.1371/journal.pone.0085128.g007
Mouse Models and In Vivo Imaging for Bone Cancers
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TC-71 Ewing sarcoma cell line. Histological examination
of femurs injected with TC-71 cells showed similar, but generally
less extensive, reactive new bone formation, typically sub-
periosteal and in association with cortical destruction. Reactive
cartilage was observed only occasionally and very focally. On CT
scans, bone destruction was the dominant appearance although
pericortical new bone was faintly evident in some mice (Fig. 1G–I).
SaOS-2 osteosarcoma cell line. In keeping with its cellular
origin, the osteosarcoma cell line SaOS-2 was unique amongst the
lines used in producing bone from the tumour cells themself (so
called ‘‘malignant’’ bone). This manifested on CT scans as rather
granular or fluffy calcification present within the extramedullary
tumour mass, sometimes well away from, and obviously discon-
tinuous with, the femoral surface (Fig. 2A, B). Histology showed
large areas in which SaOS-2 tumour cells were separated and
surrounded by pale eosinophilic unmineralised osteoid and
mineralised ‘‘malignant’’ bone with a fine, arborising, spiculate
pattern. In some areas, particularly within the medullary cavity,
‘‘malignant’’ bone showed appositional deposition on reactive or
normal bone (scaffolding) (Fig. 2C, D). The bone changes seen
histologically following intrafemoral growth of SaOS-2 cells also
included focal sub-periosteal and intra-medullary reactive new
bone formation, as well as regions of more diffuse cortical
thickening. It was difficult radiologically to distinguish periosteal
reactive new bone from the ‘‘malignant’’ bone formed by these
tumours.
PC3M prostatic adenocarcinoma cell line. As a compar-
ison to the primary bone tumour cell lines, the prostate carcinoma
cell line PC3M was used to create a model for metastatic bone
lesions. By CT scanning, injected femurs showed clear signs of
resorption of bone leading to pathological fractures of the femur in
2 of 7 injected mice (Fig. 3A). Histological examination (Fig. 3B–
D) of PC3M injected femurs often showed focal cortical
destruction and exuberant extra-medullary tumour growth with
a relatively low intra-medullary tumour burden. PC3M-induced
osteolysis was characterised by numerous resorptive pits formed by
active osteoclasts on the surface of the bone. These changes
occurred on either the periosteal or endosteal cortical surfaces,
adjacent to the tumour mass, but could be separated from the
tumour by periosteum and skeletal muscle, suggesting that PC3M
cells could induce osteoclast activation even at a distance from the
bone. Osteoclastic bone resorption was often accompanied by a
compensatory osteoblastic reaction and reactive new bone
formation on the opposite aspect of the cortex. While other
injected cell lines also induced bone destruction as large tumours
Figure 8. Bioluminescent imaging of Rag22/2 cc2/2 mice intrafemorally transplanted with transduced TC-71 cells. Weekly
bioluminescent imaging of two Rag22/2 cc2/2 mice transplanted with 56105 transduced TC-71 cells in a volume of 30 ml (25% EGFP positive cells,
top row and sorted 100% EGFP positive cells, bottom row).
doi:10.1371/journal.pone.0085128.g008
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developed, this was not characterised by the osteoclastic osteolysis
induced by PC3M.
PET Imaging of Experimental Mice
Whole body PET/CT imaging of 4 mice transplanted with VH-
64 Ewing sarcoma cell was used to characterise primary tumours
and detect possible distant tumour spread. In all cases, eyes, heart,
intestines and in some animals the brain or eyes/lacrimal glands
showed FDG accumulation. Bladder and kidneys showed FDG
signal due to renal excretion of the isotope. Muscles showed
background signal to a lesser extent in some cases. Fig. 4 shows a
representative PET/CT image of a VH-64 tumour bearing mouse
taken 52 days after transplantation (Fig. 4A) in comparison with a
day 52 PET/CT image of a mouse injected with medium alone
(Fig. 4B). PET/CT detected a tumour surrounding the right femur
in all mice injected with VH-64 cells, but not in control mice.
However, FDG-uptake was relatively low in the tumour
(SUVmean=1.5, SUVmax= 2.0 in the VH-64 tumour shown in
Figure 4A) and it should be noted that FDG uptake in other parts
of the body was substantially higher (SUVmean/SUVmax:
bladder = 14.7/20.6; intense gut region= 2.4,/3.5; muscle 0.7,/
1.4). In three VH-64 tumour bearing mice the mean (+/2 sd)
values of SUVmean were as follows: tumour 0.9+/20.1; muscle
0.6+/20.2; heart 13.7+/22.9; bladder 14.0+/29.8; gut 2.9+/
20.7). Therefore, tumour visualisation in the primary (intrafe-
moral) site was only feasible because of low uptake in leg muscle of
anaesthetised mice. Mice injected with SaOS-2 or PC3M cells,
and 1 mouse injected with TC-71 cells, did not show any evidence
of increased FDG uptake in the region of tumour formation.
Choice of anaesthetic for FDG-PET imaging. The high
FDG uptake in the heart of mice studied anaesthetised with
isofluorane made it impossible to judge whether there was
pathological involvement of the lung. A substantial reduction in
heart FDG uptake was achieved by changing from isoflurane
anaesthesia to the use of ketamine/medetomidine, as shown in
Figure 5. However, no lung deposits could be visualised by FDG-
PET using either anaesthetic technique, even when these were
histologically proven.
Figure 9. Bioluminescent imaging of of Rag22/2 cc2/2 mice intrafemorally transplanted with low numbers of transduced TC-71
cells. Weekly bioluminescent imaging of 3 Rag22/2 cc2/2 mice transplanted with 16103 (top row), 56103 (middle row) or 16104 (bottom row)
transduced TC-71 cells (EGFP sorted 1 week prior to injection). Injected cells were suspended in a volume of 10 ml. The images obtained on day 7 did
show a low signal over the right femur for all of the mice, but due to the chosen radiance settings to enable comparison with subsequent iamges,
they do not appear on this panel. On some images of mice who were not imaged individually towards the end of the experiment (i.e. middle row day
27 and 41), the reflection of a signal emitted from a neighbouring mouse is unfortunately projected onto the left femur (day 27) or left side (day 41)
of that mouse. All mice developed distant disease, either in lungs (top row), liver/abdomen (middle and bottom row) or contralateral leg (middle
row).
doi:10.1371/journal.pone.0085128.g009
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Overall, PET imaging was in principle able to detect primary
bone tumours, but given the limitations described above this
method was neither suitable for monitoring of tumour burden at
the primary site, nor as a whole body ‘‘screening tool’’ for distant
metastases.
Documentation of Soft Tissue Involvement using MRI
Where possible tumour mass was assessed by MR imaging
before dissection. In all cases, MRI was a useful technique to
visualize the tumour mass growing at the site of injection (Fig. 6,
VH-64 tumour; Supporting Fig. S2, SaOS-2 tumour and control
mouse injected with medium alone and showing normal MRI
appearances for comparison). It was possible to calculate tumour
volumes by selecting the region of interest in sections that showed
tumour mass and summing the volumes of tumour determined in
individual slices (Fig. 6).
MRI also has a potential application for detection of pathology,
including tumour metastases, in the lung and liver. In those
regions it was necessary to obtain images using respiratory gating
and, in general, good quality images could be obtained with
minimal movement artifact. Figure 7 shows two out of 25 adjacent
axial 2 mm slices, 12 mm apart, from a mouse with an
intrafemoral VH-64 Ewing tumour. The left image is an axial
upper abdominal slice depicting liver (which is largely replaced by
a tumour mass), kidney and stomach, and the right image is a slice
through the thorax showing the lungs. Although there are slight
residual movement artifacts in the thoracic images, visualisation of
any lung tumours.2 mm diameter could be expected. Thus these
images are examples of both good quality respiratory gating and
detection of distant sites of disease by MRI. Out of 6 tumour
bearing mice that underwent an end-of life MRI scan, 3 (1 VH-64
mouse and 2 PC3M mice) had detectable liver or abdominal
disease. In summary, MRI is an excellent method to obtain
anatomical detail of primary tumours and their distant metastases,
and the ability to measure tumour volumes allows for exact
monitoring of disease progression.
Bioluminescent Imaging
All but one Rag22/2 cc2/2 mice (12/13) injected with
transduced TC-71 cells showed a detectable signal over the left
femur as early as 4–7 days after i.f. injection, whereas tumours at
the site of maximum signal emission over the femur became
detectable by palpation 20 days after i.f. transplantation at the
earliest (Figure 8, Figure 9 and Table 2). One mouse injected with
16106 TC-71 cells acquired an infection shortly after the i.f.
injection and had to be culled on day 4 of experiment 1 after a
positive bioluminescent signal over the femur was confirmed. The
remaining mice lived for 24–62 days after i.f. injection. The mice
injected with higher number of tumour cells (1–56105) had a
median time of 31 days until reaching protocol limits, whereas
those mice injected with lower number of cells (16103–16104) had
a median time of 44 days before being culled.
For the mice injected with lower cell numbers (16103–16104)
in experiment 3, the increase in radiance (p/s/cm2/sr) over the
primary tumour sites with time is depicted in Figure 10. The signal
intensity at day 7 varied for mice injected with equal number of
tumour cells, with no clear correlation between cell number and
signal intensity. In addition to the primary signal over the injected
femur, signals reflecting tumour spread to lungs, bones or liver/
abdomen could be detected from 3–4 weeks after i.f. transplan-
tation. Disease spread to either lungs (n = 4), bone (n= 3), liver/
abdomen (n= 4) or kidney (n= 1) was detected in 9 out of 11 mice
by bioluminescent imaging in live mice (Figure 8, 9 and 11;
Table 2). After dissection, the lungs of one additional animal
(Figure 11), the head of another animal, and the liver/kidney of a
further animal were found to emit a weak signal whereas
previously no such signal could be detected over the respective
fields of the anaesthetized whole mice. In all but one case
examined, organs or tissues with a positive signal on in vivo
Figure 10. Timecourse of bioluminescent signal in mice injected with low numbers of transduced TC-71 cells. Depicted is the
development of signal intensity for 5 animals injected with either 16103, 56103 or 16104 cells in a volume of 10 ml. The experiment was performed
with EGFP sorted cells one week prior to injection.
doi:10.1371/journal.pone.0085128.g010
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Figure 11. Examples of bioluminescent imaging of tumour spread to bone, post mortem imaging of organs, and.the histology of
tumour spread. A, Example of a mouse transplanted with 16105 25% EGFP positive TC-71 cells with metastatic spread to the jaw, and post mortem
IVIS imaging of individual organs (dissected head, lungs and liver) demonstrating the signal from the jaw and additional weak signals from both
lungs, all of which were confirmed by histology. B, TC-71 tumour deposit contained completely within liver parenchyma as an example of visceral
tumour spread (H&E, original magnification 406). C, TC-71 tumour deposit (T) within the mandible as an example of spread to distant osseus sites.
Tng: tongue; arrowheads: teeth (H&E, original magnification 406). D, Cluster of TC-71 tumour cells within a small arterial vessel adjacent to a
bronchiole as an example of haematogenous spread (H&E, original magnification 4006). E, Cluster of TC-71 tumour cells within a lymphatic vessel
adjacent to an arterial vessel and bronchiole as an example of intralymphatic spread (H&E, original magnification 4006).
doi:10.1371/journal.pone.0085128.g011
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imaging had tumour confirmed by macroscopic examination at
autopsy or by histology. Tumour deposits presented as discrete
nodules, 0.5–12 mm in diameter, within the organ parenchyma.
In some lungs, tiny intravascular clusters of tumours cells, not
related to any larger deposits, were seen indicating haematogenous
or intralymphatic tumour spread (Figure 11). On dissection, 2
mice which were transplanted with 25% transduced TC-71 cells
were found to have additional ovarian tumours not detected by
bioluminescent imaging and likely to have arisen from non-
transduced cells injected. In summary, bioluminescent imaging
proved to be an excellent method to quantify the disease at the
primary site and also to monitor distant tumour spread in a timely
and non-invasive manner.
Discussion
In this study we have developed preclinical orthotopic models of
Ewing sarcoma and other primary and metastatic bone tumours
by injecting cells directly into the femur of young NSG or Rag22/
2 cc2/2 mice. For Ewing sarcoma, our model is the first to
combine an intraosseous orthotopic approach (i.e. injection into
bone, in contrast to periosteal or intramuscular injections) with
evaluation of different imaging approaches to monitor tumour
growth and dissemination, including disease tracking by biolumi-
nescent imaging. To our knowledge, there is only one published
Ewing sarcoma model using bioluminescent imaging to date, in
which transduced Ewing cells are injected into the periosteum/
adjacent to a rib, giving rise to chest wall tumours and pulmonary
metastases [30]. This model is more reflective of a soft tissue Ewing
sarcoma or tumour growing into the bone from the periosteum
than a truly intraosseous tumour. Other groups have examined in
various ways the interactions of human Ewing sarcoma, osteosar-
coma and prostatic carcinoma cells with murine bone in
orthotopic models [19;20;31–35]. In the present study we extend
this knowledge, showing histologically and radiologically that each
tumour type interacts with the murine bone in a specific way
resembling human clinical disease, validating our model as one in
which the growth, spread and treatment of Ewing sarcoma can
meaningfully be investigated.
Although other orthotopic approaches (e.g. intratibial injection)
are available [18;19;20], our model offers several advantages. One
advantage of an intrafemoral model is the good accessibility of the
femur achieved by bending the knee and accessing it through the
distal end. As with intratibial transplantation, intrafemoral
injection is minimally invasive and non-traumatic, but the larger
size of the femur can facilitate the transplantation procedure. The
technique can be performed on animals from approximately 6
weeks of age. Secondly, the NSG and Rag22/2 cc2/2 mice used
are severely immunocompromised, allowing tumour induction in
almost 100% of animals injected. Previous work has used
intravenous injections to model the metastasis of Ewing sarcoma
cell lines in vivo but bone metastasis is uncommon in this model
and metastases hard to identify [16]. In the present orthotopic
model, the observed pattern of spread of Ewing sarcoma cells was
similar to the human cancer (primarily lung and bone), supporting
the clinical relevance of the model. The histological findings are
most consistent with a haematogenous or intralymphatic mode of
tumour spread. However, although the appearance of distant
tumour spread was significantly delayed in comparison to
development of the primary tumour, the possibility that some
tumour spread resulted from inadvertent innoculation of tumour
cells into the circulation at the time of i.f. injection cannot entirely
be excluded. Reassuringly, we only ever saw tumour involvement
of the synovium or capsule of the knee joint in association with
late-stage destruction of the distal femoral cortex induced by
outgrowth of intrafemoral tumour, which makes significant
spillage from the needle track back into the knee joint unlikely.
We also initially observed ovarian metastases in two Rag22/2
cc2/2 mice. As ovarian metastases are rather rare in the human
disease, but have been observed in female animals from previous
experiments [16], further experiments were conducted in male
mice only, in order to better mirror the metastatic spread of Ewing
sarcoma in humans.
To reduce the chance of tumour cell injection into the
circulation, and also to not ‘‘overwhelm’’ the bone marrow cavity
with large numbers of tumour cells, during development of the
model we reduced the volumes injected by 66% (from 30 ml to
10 ml) and the number of tumour cells 100–1000 fold (down to
1000 cells). The resulting histological findings at post-mortem and
the bioluminescent signals over time were very similar to earlier
experiments using more cells in a higher volume, albeit with a
slightly longer time for the animals to reach protocol limits
(median 31 days for animals injected with 1–5 6 105 cells vs.
median of 44 days for animals injected with 16103–16104 cells).
For other published Ewing sarcoma models, cell numbers vary
from 26105 cells in 20 ml injected into the tibia [20], to 56105
cells in 20 ml injected around the periosteum of a rib [30] or to 1–
26106 cells injected into the gastrocnemius muscle [36,37] or the
tibia [19]. Thus, we have here used the lowest number of cells for
an orthotopic intraosseous injection reported in the literature so
far, making this model the least likely to cause any non-
physiological local side effects.
As the ability to image growing tumours greatly enhances the
preclinical utility of in vivo tumour models, we assessed the
usefulness of FDG-PET, CT, MRI and bioluminescent imaging
in our orthotopic model. Previous work has used FDG- and [18F]-
PET to examine metastatic tumour sites in mice transplanted
intravenously with Ewing sarcoma cell lines [38]. However, due to
the evaluation of summation plots as opposed to individual planes
in this study, the tumours in this intrafemoral orthotopic model
showed a relatively low signal intensity compared to host organs.
Thus, FDG-PET was of limited value in the assessment of the
tumours and detection of possible metastases. In contrast, MR
imaging proved superior for the monitoring and measurement of
the extra-osseous soft tissue components of the tumours induced.
Additionally, in half of the mice that underwent an abdominal
scan, MRI was able to detect metastases to the liver or peritoneal
cavity. As expected, CT imaging provided excellent results for the
visualisation of tumour-associated bone alterations, showing both
the extent and distribution of reactive and ‘‘malignant’’ bone
formation and the degree of bone destruction/resorption in the
Table 2. Summary of TC-71 bioluminescent signal detection
in live mice and post-mortem (after dissection).
Organ In live mice Post mortem
femur 12/13 4/4
lungs 4/11 4/5
kidneys 1/11 1/5
Liver/abdomen 4/11 1/5
distant bone 3/11 2/5
One mouse with an IVIS-positive femoral tumour was culled on day 4 and could
not be assessed for metastatic spread. Post mortem bioluminescence imaging
of dissected organs was performed on 5 animals. The involved leg of one of
these had been removed before imaging.
doi:10.1371/journal.pone.0085128.t002
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region of the implanted tumour. CT and MR imaging provided
complementary information and such a combined modality
approach is important for imaging bone tumours in vivo. Biolumi-
nescent imaging was the superior method regarding practicability
and performing imaging in a timely fashion for monitoring the
development of primary and metastatic disease to different organs
such as lungs, liver and bone, despite lacking the anatomical detail
of CT or MRI imaging. However, tumour deposits arising from
co-transplanted non-transduced tumour cells can lead to disease
which is subsequently missed on bioluminescent imaging. There-
fore, it is preferable to purify transduced cells before transplan-
tation to minimise false negative results using vectors with
selectable markers, such as EGFP. An even better consistency
between signal and injected cell numbers and thus a better
monitoring of disease burden over time might be obtained by
selecting a monoclonal cell population for transplantation.
Christoph et al. have recently compared monoclonal and poly-
clonal luciferase transduced cell populations in vitro and in vivo
[39]. They have shown that for monoclonal populations of firefly
luciferase transduced leukaemia cell lines, the luciferase activity
was stable and light emission correlated strongly with cell
numbers, leading to a consistent disease burden between animals.
By combining CT imaging with histological examination we
have demonstrated that each of the cell lines used interacted with
the bone microenvironment, altering bone structure, in charac-
teristic ways. This finding confirms that our transplantation
procedure preserves the mouse bone microenvironment in such
a way that clinically relevant and tumour type-specific tumour-
bone interactions may occur. Both Ewing sarcoma cell lines,
particularly VH-64, induced florid reactive new bone formation
consistent with pronounced periosteal reactions. In VH-64
transplanted mice, this was detected radiologically as spiculated
new bone radiating perpendicularly from the cortex in a
‘‘sunburst’’ appearance. Although clinical Ewing sarcomas often
produce a laminated ‘‘onion-skin’’ pattern of new bone, a
‘‘sunburst’’ pattern is seen in approximately 25% of cases [40].
The predominance of this pattern in the present model may reflect
the relatively rapid tumour growth in the model compared to that
in patients. While reactive new bone and cartilage formation may
be seen in response to fracture, we do not believe that this is the
predominant pathological process in our model as the degree of
new bone formation was not correlated with the degree of bone
destruction and fractures were seen in PC3M transplanted mice,
which showed little new bone formation.
Injection of the murine femurs with cells of a human
osteosarcoma cell line (SaOS-2) induced some reactive trabecular
bone and cortical thickening, but most notable was the intra-
tumoural deposition of osteoid, within which formed mineralised
‘‘malignant’’ bone. It can be concluded that this cell line is able to
mature within the in vivo environment to form osteoid and bone in
a manner similar to that seen in patients. The human prostate
cancer cells (PC3M) caused pronounced osteolytic lesions within
the murine femurs, leading to pathological fractures in some cases.
This is in contrast to most bone metastases in advanced stage
prostate carcinoma, which more commonly show osteoblastic/
osteosclerotic characteristics. However, we have used this cell line
as a model of osteolytic bone metastasis rather than metastatic
prostatic carcinoma per se, and our findings are consistent with
both the derivation of this cell line from a clinically osteolytic
metastasis [24] and the generation of osteolytic bone lesions in
other PC-3 xenograft models [18]. The different responses of the
host bone to the different tumour types is consistent with a model
in which specific reciprocal interactions between tumour cells and
cells of the bone microenvironment cooperate to disturb normal
bone homeostasis resulting in uncoupled bone remodelling.
Experimental evidence suggests that these characteristic bone
changes may support the growth of tumour in the metastatic
environment [41] and they may also result in direct or indirect
clinical morbidity. Understanding these interactions in models
such as that described here is thus essential for the development of
future therapies aimed at tumours within bone.
In conclusion, we have established an orthotopic human-mouse
xenograft model that mirrors remodelling of normal bone by
primary and secondary bone tumours and which will be of value
for future studies analysing the interaction between malignant cells
and the bone microenvironment. The model for Ewing sarcoma is
the first reported combining an intraosseous orthotopic injection
approach (using minimal numbers of injected cells) with biolumi-
nescent imaging. The model could be further improved by
selecting a single clone of transduced cells to achieve more
consistent signal emission for different numbers of injected cells, or
by transplanting primary patient material. In combination with
MRI and bioluminescent imaging, our model has the potential to
serve as a valuable tool for preclinical studies to assess the efficacy
of newly developed pharmaceuticals for the treatment of both
primary bone tumours and secondary metastases. Bioluminescent
imaging allows for efficacious monitoring of disease progression
and spread in vivo, which is a prerequisite for testing of anti-
metastatic approaches. In summary, our models for a variety of
bone cancers, including the first with the potential for in vivo
tracking of Ewing sarcoma, will widely benefit bone cancer
research and promote the translation of novel therapeutic
approaches into clinical practice.
Supporting Information
Figure S1 Histology and CT imaging of a control
mouse. A, Representative CT image (near sagittal section
through the right knee and femur) 42 days after injection of a
control mouse injected with medium alone, showing normal
appearances. B, Representative Maximal Intensity Projection CT
image 85 days after injection depicting both lower extremities of a
control mouse injected with medium alone, showing normal
apperances. C, Representative histological section of right femur
from a control mouse injected with medium alone, showing
normal bone and skeletal muscle (H&E, original magnification
406).
(TIF)
Figure S2 MRI imaging of control mouse and mouse
injected with SaOS-2 cells. A, MRI scan on day 85, showing
the legs of a control mouse injected with medium alone. B, MRI
scan on day 85, showing a tumour in the right leg of a mouse
injected with SaOS-2 cells (arrow).
(TIF)
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